Hookipa Pharma
NYC-based Hookipa pioneers in developing superior immunization therapies for infections and cancer.
Founded
2011NYC-based Hookipa pioneers in developing superior immunization therapies for infections and cancer.
Founded in New York City, Hookipa Pharma is a clinical-stage biotech company dedicated to developing advanced immunization therapies for infectious diseases and oncology. Their core mission is to harness the power of the immune system to create best-in-class treatments that offer superior efficacy and safety. Hookipa's innovative approach focuses on leveraging CD8+ T cells to target and destroy cancer cells, as well as combat infectious pathogens. The company aims to revolutionize the landscape of immunotherapy through its cutting-edge research and development.
Hookipa Pharma has garnered attention from notable investors and industry leaders, contributing to its rapid growth and recognition in the biotech sector. The company's key achievements include presenting positive clinical data at prestigious conferences such as the American Society of Clinical Oncology. These milestones underscore Hookipa's potential to make significant impacts in the fields of infectious disease and cancer treatment. Through their pioneering work, Hookipa Pharma is poised to transform immunotherapy, offering new hope to patients worldwide.
Companies similar to Hookipa Pharma include Immunome, Immunophotonics, OncoPep and ImmunityBio.
Hookipa Pharma was founded in 2011.
Hookipa Pharma's headquarters is located in New York City, NY, US.
Hookipa Pharma's most recent funding round was for A$21.3M (AUD) in December 2023.
As of Dec 21, 2023, Hookipa Pharma has disclosed funding of $288.6M (USD). Undisclosed round amounts are excluded.
Hookipa Pharma has 136 employees as of Feb 6, 2024.
